2. Search Result
Search Result
Results for "

SMN protein

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Recombinant Proteins

3

Isotope-Labeled Compounds

5

Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-109101
    Risdiplam
    5+ Cited Publications

    RG7916; RO7034067

    		 DNA/RNA Synthesis Neurological Disease
    Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .
    Risdiplam
  • HY-112980
    Nusinersen
    4 Publications Verification

    		 DNA/RNA Synthesis Neurological Disease
    Nusinersen is an antisense oligonucleotide active molecule. Nusinersen modifies the pre-messenger RNA splicing of the SMN2 gene, thereby promoting the production of full-length SMN protein. Nusinersen improves spinal muscular atrophy .
    Nusinersen
  • HY-19620
    Branaplam
    Maximum Cited Publications
    15 Publications Verification

    LMI070; NVS-SM1

    		 DNA/RNA Synthesis Potassium Channel Cancer
    Branaplam (LMI070; NVS-SM1) is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model .
    Branaplam
  • HY-112980A
    Nusinersen sodium
    4 Publications Verification

    		 DNA/RNA Synthesis Neurological Disease
    Nusinersen sodium is an antisense oligonucleotide active molecule. Nusinersen sodium modifies the pre-messenger RNA splicing of the SMN2 gene, thereby promoting the production of full-length SMN protein. Nusinersen sodium improves spinal muscular atrophy .
    Nusinersen sodium
  • HY-124293
    AA147
    4 Publications Verification

    		 ATF6 Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease
    AA147 is a endoplasmic reticulum (ER) proteostasis regulator. AA147 promotes protection against oxidative damage in neuronal cells and prevents endothelial barrier dysfunction by activating ATF6 arm (selectively) of the unfolded protein response (UPR) and the NRF2 oxidative stress response. AA147 can rebalances XBP1s expression in vivo, and also induces survival motor neuron (SMN) expression and spinal motorneuron (MN) protection .
    AA147
  • HY-19620A
    Branaplam hydrochloride
    Maximum Cited Publications
    15 Publications Verification

    LMI070 hydrochloride; NVS-SM1 hydrochloride

    		 DNA/RNA Synthesis Potassium Channel Cancer
    Branaplam (LMI070; NVS-SM1) hydrochloride is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam hydrochloride inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam hydrochloride elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model .
    Branaplam hydrochloride
  • HY-124648
    SMN-C2

    		DNA/RNA Synthesis Inflammation/Immunology
    SMN-C2, an analog of RG-7916, is a selective modulator of SMN2 gene splicing that acts by binding SMN2 pre-mRNA, thereby increasing far upstream element binding protein 1 (FUBP1) and KH-spliced RNA binding Protein affinity regulator protein (KHSRP) to the SMN2 pre-mRNA complex. SMN-C2 can be used in spinal muscular atrophy (SMA) research .
    SMN-C2
  • HY-101792A
    RG7800 tetrahydrochloride
    5 Publications Verification

    RO6885247 tetrahydrochloride

    		 DNA/RNA Synthesis Neurological Disease
    RG7800 hydrochloride is an orally active SMN2 splicing modulator, with EC1.5xs of 23 nM and 87 nM for SMN2 splicing and SMN protein; RG7800 hydrochloride has the potential to treat spinal muscular atrophy.
    RG7800 tetrahydrochloride
  • HY-111520
    NVS-SM2

    		DNA/RNA Synthesis Neurological Disease
    NVS-SM2 is a potent, orally active and brain-penetrant SMN2 splicing enhancer with an EC50 of 2 nM for SMN. NVS-SM2 enhances U1-pre-mRNA association. NVS-SM2 promotes exon 7 inclusion and restores normal survival motor neuron (SMN) protein expression. NVS-SM2 can be used for spinal muscular atrophy (SMA) research .
    NVS-SM2
  • HY-124713
    ML372

    		DNA/RNA Synthesis Neurological Disease
    ML372 inhibits survival motor neuron (SMN) protein ubiquitination, increases SMN protein stability without affecting mRNA expression. ML372 improves spinal muscular atrophy (SMA) in mice. ML372 is brain penetrant and has a reasonable exposure and half-life in vivo .
    ML372
  • HY-109101S
    Risdiplam-d4
    1 Publications Verification

    		 DNA/RNA Synthesis Neurological Disease
    Risdiplam-d4 is deuterium labeled Risdiplam. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .
    Risdiplam-d4
  • HY-117000A
    D156844 hydrochloride

    		DNA/RNA Synthesis Dihydrofolate reductase (DHFR) Neurological Disease
    D156844 (Compound 11a) hydrochloride is a SMN2 promoter activator with an EC50 of 4 nM. D156844 hydrochloride increases the mRNA expression of the mouse SMN in NSC-34 cells and human SMN2 promoter in severe type I spinal muscular atrophy (SMA) fibroblasts as well as full-length human SMN protein. D156844 hydrochloride overcomes DHFR inhibition. D156844 hydrochloride can be used for SMA research .
    D156844 hydrochloride
  • HY-109101R
    Risdiplam (Standard)

    RG7916 (Standard); RO7034067 (Standard)

    		 Reference Standards DNA/RNA Synthesis Neurological Disease
    Risdiplam (Standard) is the analytical standard of Risdiplam. This product is intended for research and analytical applications. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .
    Risdiplam (Standard)
  • HY-117000
    D156844

    		DNA/RNA Synthesis Dihydrofolate reductase (DHFR) Neurological Disease
    D156844 (Compound 11a) is a SMN2 promoter activator with an EC50 of 4 nM. D156844 increases the mRNA expression of the mouse SMN in NSC-34 cells and human SMN2 promoter in severe type I spinal muscular atrophy (SMA) fibroblasts as well as full-length human SMN protein. D156844 overcomes DHFR inhibition. D156844 can be used for SMA research .
    D156844
  • HY-109101AS2
    Risdiplam-hydroxylate-d6

    		Isotope-Labeled Compounds DNA/RNA Synthesis Neurological Disease
    Risdiplam-hydroxylate-d6 is a Risdiplam-hydroxylate tritium substitute. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .
    Risdiplam-hydroxylate-d6
  • HY-109101AS1
    Risdiplam-hydroxylate-d3

    		Isotope-Labeled Compounds DNA/RNA Synthesis Neurological Disease
    Risdiplam-hydroxylate-d3 is a Risdiplam-hydroxylate tritium substitute. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .
    Risdiplam-hydroxylate-d3
  • HY-119460
    Cuspin-1

    		ERK Neurological Disease
    Cuspin-1 is a upregulator of Survival of Motor Neuron protein (SMN). Cuspin-1 upregulates SMN expression post-transcriptionally, and increases the phosphorylation of Erk. Cuspin-1 can be used for research of neurodegenerative disease, such as spinal muscular atrophy (SMA) .
    Cuspin-1
  • HY-124640
    SMN2 modulator-1

    		DNA/RNA Synthesis Neurological Disease
    SMN2 modulator-1 is a brain-penetrant survival motor neuron (SMN) modulator. SMN2 modulator-1 post-translationally stabilizes SMN protein and increases SMN protein levels independent of SMN2 transcription. SMN2 modulator-1 can be used for the research of spinal muscular atrophy[1].
    SMN2 modulator-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: